论文部分内容阅读
目的对重组人脑钠肽治疗失代偿性心力衰竭的临床疗效进行研究分析。方法 58例失代偿性心力衰竭患者,随机分为研究组和对照组,每组29例。对照组患者使用常规治疗,研究组患者在其基础上给予重组人脑钠肽治疗,比较两组失代偿性心力衰竭患者的临床疗效及呼吸、心率、尿量情况。结果研究组患者总有效率为93.10%,对照组患者总有效率为68.97%,研究组总有效率明显高于对照组,差异具有统计学意义(P<0.05)。研究组患者治疗后呼吸为(22.20±1.79)次/min、心率为(75.46±8.20)次/min、尿量为(1420.41±637.45)ml/12 h,均优于对照组的呼吸(25.40±2.15)次/min、心率(81.14±9.20)次/min、尿量(1010.43±586.34)ml/12 h,差异具有统计学意义(P<0.05)。结论采用重组人脑钠肽治疗失代偿性心力衰竭患者效果显著,在临床上可以广泛应用。
Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of decompensated heart failure. Methods 58 patients with decompensated heart failure were randomly divided into study group and control group, with 29 cases in each group. Patients in the control group were treated with conventional therapy. Patients in the study group were given recombinant human brain natriuretic peptide (BNP) on the basis of the results. The clinical effects, respiration, heart rate and urine output of the patients in the decompensated HF group were compared. Results The total effective rate was 93.10% in the study group and 68.97% in the control group. The total effective rate in the study group was significantly higher than that in the control group (P <0.05). After treatment, the respiration rate of the study group was (22.20 ± 1.79) / min, the heart rate was (75.46 ± 8.20) / min and the urine output was (1420.41 ± 637.45) ml / 12 h, 2.15) times / min, heart rate (81.14 ± 9.20) times / min, urine output (1010.43 ± 586.34) ml / 12 h, the difference was statistically significant (P <0.05). Conclusion Recombinant human brain natriuretic peptide in patients with decompensated heart failure has a significant effect and can be widely used clinically.